Welcome back to another episode of Derms on Drugs—where we prescribe only the highest yield practical pearls (and zero prior authorizations are ever required). If dermatology conferences make you yawn but a six-pack of journal articles gets your heart racing, you’re definitely in the right clinic!
What’s on Tap in Our 6 Pack Episode?
Today, we’re serving up a refreshing six-pack—no ice needed, but plenty of cool research to keep you hydrated with knowledge:
So scrub in, sit back, and let us put the “fun” in fundamentals as we break down the latest, greatest (and occasionally weirdest) in the world of clinical dermatology. Let’s pop open that six-pack and get started.
And for links to all of the articles we discussed in this episode, visit ScholarsInMedicine.com
Welcome to another episode of Derms on Drugs, where we peel back the layers on the latest in dermatology therapeutics. Today, we’re thrilled to have Dr. Donna Culton join us for a deep dive into the world of bullous pemphigoidIn this episode we:
So, whether you’re a seasoned derm or just here for the laughs, tune in as we blister through the data and get under the skin of bullous pemphigoid’s newest treatment frontier.
For Links to articles please go to ScholarsinMedicine.com
1. Bullous pemphigoid: A practical approach to diagnosis and management in the modern era
2. Effectiveness of Dupilumab and Omalizumab in Bullous Pemphigoid: A Nationwide Retrospective Cohort Study
3. Study Design of a Phase 2/3 Randomized Controlled Trial of Dupilumab in Adults with Bullous Pemphigoid: LIBERTY-BP ADEPT
Welcome to the first-ever Derms on Drugs Debate! Our brave hosts tackle three of the hottest—and most controversial—questions in the field:
Castle Gene Expression Profile in Melanoma: Should dermatologists use it for almost every melanoma, just those “close to 1 mm,” or leave it to the oncologists?
Zoryve, VTAMA and Opzelura: All great drugs, but if you could only keep one, which would it be? Our hosts go head-to-head to defend their picks.
The Next Game Changer in Dermatology: Will it be AI-powered skin cancer diagnosis, BTK inhibitors, or the first generic oral JAK? Hear our predictions and the cases for each.
Whether you’re a dermatology provider, researcher, or pharma professional, you’ll get expert insights, practical takeaways, and plenty of lively debate—Derms on Drugs style.
Tune in for clinical pearls, bold opinions, and a fresh look at the future of dermatology. Don’t miss out—hit play and join the debate!
Ready to level up your medical dermatology game? This week, Derms on Drugs tackles the toughest questions and latest controversies in serious derm—served with our signature practical, no-nonsense style with a big dose of humor.
We break down the newest literature and answer:
Does immunotherapy really help with high-risk squamous cell carcinoma?
Are pemphigus patients getting more rituximab than they need?
Why don’t JAK inhibitors increase cardiovascular risk in atopic dermatitis?
Is the Mind.Px test actually helpful for picking a psoriasis biologic?
What does drug level monitoring tell us about adalimumab in hidradenitis suppurativa?
Which treatment factors predict scabies cure?
Perfect for dermatology providers and industry pros who want clinical pearls, evidence-based answers, and a few laughs along the way. Tune in for the most fun you’ll have while getting smarter about serious medical derm!
Hit play and stay on the cutting edge of medical dermatology!
1. Adjuvant Cemiplimab or Placebo in HighRisk Cutaneous Squamous-Cell Carcinoma
2. Efficacy, safety, and B-cell depletion capacity of three rituximab dosing regimens in the treatment of moderate-to-severe pemphigus vulgaris and pemphigus foliaceus: a 52-week clinical trial
3. Understanding Cardiovascular Events With JAK Inhibitors: Tofacitinib Reduces Synovial and Vascular Inflammation but not the Prothrombotic Effects of Inflammatory Cytokines on Endothelium
4. Is Upadacitinib Cardioprotective in Chronic Inflammatory Diseases? A Review of Major Adverse Cardiovascular Events and Venous Thromboembolism in Atopic Dermatitis
5. Clinical Utility Findings of a Transcriptomic Psoriasis Biologic Test Demonstrate Altered Physician Prescribing Behavior and Improved Patient Outcomes
6. Therapeutic Drug Monitoring in Hidradenitis Suppurativa Patients With Suboptimal Treatment Response to Adalimumab
7. Scabies Management Outcomes: Identification of Risk Factors for Treatment Success or Failure
Chronic Spontaneous Urticaria (CSU) is back in the dermatology spotlight—and for good reason. Join the Derms on Drugs as we break down the latest clinical trial data on Dupixent (dupilumab) and the buzzworthy new oral BTK inhibitor, remibrutinib, both showing real promise for CSU patients who’ve hit a wall with antihistamines.
We’re joined by CSU expert Dr. Jason Hawkes to discuss:
-How Dupixent is changing the game for CSU and why dermatologists are leading the charge
-What makes remibrutinib “fast, sexy, and safe”—plus what the new Phase III data means for your patients
-How we explain to CSU patients that they don’t need allergy testing!
-Clinical pearls for work-up, navigating treatment guidelines, safety, and access
Perfect for derm providers who want the latest on CSU pathophysiology, emerging therapies, and patient communication. Tune in for actionable insights, expert commentary, and a dose of Derms on Drugs humor—because managing hives shouldn’t be a headache.
Hit play and stay ahead on the cutting edge of CSU care!
1. Autoimmune Thyroid Diseases in Chronic Spontaneous Urticaria: The Role of Hormones, Anti-Thyroid Antibodies, and Ultrasound
2. Remibrutinib in Chronic Spontaneous Urticaria
3. Dupilumab in patients with chronic spontaneous urticaria (LIBERTY-CSU CUPID): Two randomized, double-blind, placebo-controlled, phase 3 trials
Ready to stay ahead in dermatology? Join the Derms on Drugs for a fast-paced, practical dive into the hottest new research and trends shaping our specialty.
This week, we break down:
Surprising long-term data comparing Dupixent and Rinvoq for atopic dermatitis
The future of autoimmune disease treatment: genetically modified T cells
What policies people actually support (and will pay for) to reduce skin cancer rates
JAK inhibitors for mucosal pemphigoid—what’s new, what works, and what to watch for
The latest on rising contact allergens: which ones are on the move and why
Packed with clinical pearls, practical tips, and a dash of humor, this episode is your shortcut to what’s new, what’s changing, and what you can use in practice right now.
Don’t miss out—hit play for your weekly dose of dermatology insights!
For links to all articles visit ScholarsinMedicine.com
1. Local immune effector cell-associated toxicity syndrome in CAR T-cell treated patients with autoimmune disease: an observational study
2. Janus Kinase Inhibitors in the Treatment of Refractory Cicatrizing Conjunctivitis in Pemphigoid
3. Long-Term Real-World Effectiveness of Dupilumab vs. Upadacitinib in early Treatment Responders with Atopic Dermatitis: Results from Central European Health Fund Registry
4. Mid-term effectiveness, safety, and potential predictors of response of upadacitinib in patients with moderate-to-severe atopic dermatitis: a multicenter observational retrospective study
5. Ivarmacitinib for Moderate to Severe Atopic Dermatitis in Adults and Adolescents
6. Public preferences for skin cancer prevention policies: a discrete choice experiment in three European countries
7. North American Contact Dermatitis Group Patch Test Results: 2021–2022
Ever feel overwhelmed by the flood of alopecia treatments and supplements?
Join the Derms on Drugs as we cut through the noise with Dr. Michelle Tarbox, diving deep into the practical side of managing alopecia for dermatology providers.
In this episode, we tackle:
Tune in for expert insights, practical tips, and a healthy dose of humor—perfect for medical providers who want to stay ahead in dermatology without getting lost in the latest hype.
Listen now for all the answers—and maybe a few laughs!
Hair loss is common and devastating, both to the person losing their hair and the dermatology provider taking care of them. Derms on Drugs to the rescue. In part one of our deep dive into hair loss we cover three big topics: 1) What supplements for hair loss actually work? You'll have heard (ad nauseum) about some of them, but we'll also bring you some ideas for cheap supplements you haven't heard of that actually work; 2) Do we really need to do lab work-ups in patients with telogen effluvium? and 3) What's the state of the art when it comes to diagnosing and managing folliculitis decalvans? Join us for another episode with our trademark mix of evidence and banter! #DermatologyPodcast #HairLoss #DermsOnDrugs #Alopecia
Produced by ScholarsinMedicine.com
1. Management of folliculitis decalvans: The EADV task force on hair diseases position statement
2. Retrospective Review of 2851 Female Patients With Telogen Effluvium: A Single-Center Experience
3. Impact of Laboratory Work Up and Supplementation on Alopecia Patients: A Single-Center Retrospective Chart Review
4. Evaluation of the Safety and Effectiveness of Nutritional Supplements for Treating Hair Loss A Systematic Review
Join Derms on Drugs for a must-hear episode packed with practical dermatology updates!
Discover if Nutrafol Acne delivers, which skin care ingredients top cosmetic dermatologists swear by, and the latest breakthroughs for hand eczema. Plus, is Zoryve Foam a game-changer for psoriasis? And what’s the deal with PRAME staining for benign nevi? Get actionable insights to elevate your practice along with our usual banter.
Derms on Drugs is produced by Scholars in Medicine.
Resource links can be found at: Scholarsinmedicine.com
1. A 12-Week Randomized, Double-Blind, Placebo-Controlled Trial for the Efficacy and Safety of a Novel Nutraceutical for Mild-to-Moderate Acne
2. Skincare Ingredients Recommended by Cosmetic Dermatologists: A Delphi Consensus Study
3. Efficacy and safety of topical delgocitinib cream versus oral alitretinoin capsules in adults with severe chronic hand eczema (DELTA FORCE): a 24-week, randomised, head-to-head, phase 3 trial
4. Oral roflumilast for the treatment of chronic hand eczema: a retrospective case series
5. Roflumilast Foam, 0.3%, for Psoriasis of the Scalp and Body
6. Clinicopathologic Features of PRAME-Positive Common Melanocytic Nevi: A Case-Control Study
Skyrocketing drug prices are hitting dermatology hard. Why are Americans paying more than other countries? Are Pharmacy Benefit Managers (PBMs) or pharmaceutical companies to blame? Join Derms on Drugs as our experts pull back the curtain on the broken system driving costs. Get insider insights, practical takeaways, and our trademark banter to navigate this mess as a clinician.
Derms on Drugs is a production of Scholarsinmedicine.com
1. Use and Cost of First-Line Biologic Medications to Treat Plaque Psoriasis in the US
2. Systematic review and estimated cost-efficacy of biologics compared with narrowband ultraviolet B light for the treatment of moderate to severe psoriasis and atopic dermatitis
3. AI Description and Answers About How Drug Pricing Works
Scholarsinmedicine.com
Join Derms on Drugs for a riveting dive into artificial intelligence and automated skin cancer detection.
World-renowned expert Dr. Laura Ferris, with 20 years in the field, breaks down cutting-edge research and predicts the future of dermatology. Will AI "terminate" dermatologists or empower us to focus on complex cases and patient care? Expect fresh insights, practical takeaways, and lively banter that’ll make you a smarter clinician. Don’t miss this chance to stay ahead in the AI revolution!
Derms on Drugs is produced by Scholars In Medicine
For Resources links visit: Scholars In Medicine
1. Diagnostic performance of augmented intelligence with 2D and 3D total body photography and convolutional neural networks in a high-risk population for melanoma under real-world conditions: A new era of skin cancer screening?
2. 3D Total-Body Photography in Patients at High Risk for Melanoma
3. Promises and Pitfalls of 3D Total-Body Photography for Melanoma Early Detection
4. Real-world post-deployment performance of a novel machine learning-based digital health technology for skin lesion assessment and suggestions for post-market surveillance
5. Standard Dermatoscope Images vs an Autonomous Total Body Photography and Dermoscopic Imaging Device
Produced by Scholars in Medicine.com
Tune in to Derms on Drugs for a the most fun you can have while diving into the hottest dermatology topics! This week, we unpack cutting-edge insights from the latest literature to make you a sharper clinician. Explore adjuvant therapy for Stage 3A melanoma, the pitfalls of dermatomyositis misdiagnosis, and a surprising finding: is hydroxychloroquine outperforming NBUVB for vitiligo? Plus, discover new skin-gut-immune connections, tackle cancer immunotherapy-induced pemphigoid, and learn how to manage premenstrual rash flares in atopic dermatitis, contact dermatitis, and autoimmune progesterone dermatitis. Join our fun, banter-filled discussion to stay ahead in dermatology!
In This Episode:
Stage 3A Melanoma: Is adjuvant therapy worth it, and what’s the best option?
Dermatomyositis: Consequences of misdiagnosis and delayed diagnosis
Vitiligo: Could hydroxychloroquine be a game-changer over NBUVB?
Skin Inflammation: A key driver of food allergy
Pemphigoid: Insights into immunotherapy-induced cases
Premenstrual Rashes: Managing flares in atopic,
1. Efficacy of adjuvant therapy in patients with stage IIIA cutaneous melanoma.
2. Patterns and Clinical Implications of Misdiagnosis in Dermatomyositis
3. Effectiveness, Tolerability and Safety of Topical Clobetasol with Oral Hydroxychloroquine versus Topical Clobetasol with NBUVB Phototherapy in Unstable Vitiligo: Investigator Blind, Randomized Controlled Trial
4. Skin damage signals mediate allergic sensitization to spatially unlinked antigen
5. Epitope Spreading in Immune Checkpoint Inhibitor–Associated Bullous Pemphigoid
6. The impact of the menstrual cycle on exacerbations of atopic dermatitis: a systematic review
7. Nickel contact allergy and menstrual cycle
8. Autoimmune progesterone dermatitis: Update and insights
Should dermatologists offer Image Guided Superficial Radiation Therapy (IGSRT) in-office or refer radiation oncologists when radiation is appropriate? Join Derms on Drugs as we tackle this "burning" question with two expert radiation oncologists. While dermatologists are THE skin cancer experts, radiation therapy isn't our usual domain— so is IGSRT a game-changer for your practice or too far outside our realm? Explore clinical insights, practical considerations, and the latest evidence to guide your decision-making. Perfect for dermatologists, PAs, NPs, residents, medical students, and pharma professionals in dermatology seeking to stay ahead of the curve. Tune in to discover if IGSRT could light up your approach to patient care—or leave you glowing in the dark.
#Dermatology #SkinCancer #IGSRT #RadiationTherapy #DermEducation
1. Updated results of 3,050 non-melanoma skin cancer (NMSC) lesions in 1725 patients treated with high resolution dermal ultrasoundguided superficial radiotherapy, a multiinstitutional study
2. The Role of Image-Guided Superficial Radiation Therapy in the Treatment of Nonmelanoma Skin Cancer
3. Effectiveness and Patient Experiences of Rhenium Skin Cancer Therapy for Nonmelanoma Skin Cancer: Interim Results from the EPIC-Skin Study
Buckle up for a whirlwind tour of the hottest dermatology literature. This week, we’ve got the deets on:
Hidradenitis suppurativa itch: Dermeleve’s here to make HS patients stop scratching and start living.
Join us for laughs, learning, and maybe a few gasps as we unpack the science that’s got the derm world buzzing. Perfect for dermatologists, PAs, NPs, pharma folks, and students who live for skin-deep insights. Subscribe, share, and let’s make dermatology lit! #DermatologyPodcast #DermLife
When a pathology report says 'melanoma,' the stakes are high. How confident are you in the diagnosis? Should you order gene expression profiling for better prognostic insights—or is it overrated?
Join the Derms on Drugs as we dig into the challenges of melanoma diagnosis and management. This week, we’re thrilled to feature Dr. Whitney High from the University of Colorado, the best-of-the-best dermatopathology expert, to share evidence-based answers with the Derms on Drugs flare our listeners expect.
Derms on Drugs is brought to you by Scholars in Medicine.
Resource links for this episode are available at Scholars in Medicine.
1. Society of Surgical Oncology Consensus Statement: Assessing the Evidence for and Utility of Gene Expression Profiling of Primary Cutaneous Melanoma
2. 31-GEP (DecisionDx): a review of clinical utility and performance in a Mayo Clinic cohort
3. CLO25-055: Metastasis-Free Survival Prediction With the 40-Gene Expression Profile Test in Patients With Cutaneous Squamous Cell Carcinoma Risk Stratified According to the National Comprehensive Cancer Network Guidelines
4. CGE25-104: The 31-GEP Identifies Patients With Early-Stage I-IIA Cutaneous Melanoma at High Risk of Melanoma-Specific and Overall Mortality
Does Dupixent raise the risk of cutaneous T-cell lymphoma (CTCL) in atopic dermatitis patients? It’s the burning question gripping dermatology—and we’ve got answers.
Join the Derms on Drugs team as we unpack the latest with Dr. Shamir Geller, who runs a CTCL clinic at Memorial Sloan Kettering and published the first data that truly helps us understand if there is a Dupixent - CTCL link.
Plus, we dive into CTCL survival stats and must-know updates for practicing dermatologists. Essential listening for anyone who is taking care of dermatology patients.
Derms on Drugs is brought to you by Scholars in Medicine.
Guest: Shamir Geller, MD
Associate Attending Physician Dermatology Service, Department of Medicine Memorial Sloan Kettering Cancer Center, New York, NY
Associate Professor of Clinical Dermatology, Department of Dermatology, Weill Cornell Medicine, New York, NY
I’m a dermatologist interested mainly in cutaneous lymphoma. During my cutaneous oncology fellowship at Memorial Sloan Kettering Cancer Center (MSK) between the years 2016-2019, I became a cutaneous lymphoma enthusiast, working at MSK multi-disciplinary cutaneous lymphoma clinic. Under the mentorship of expert faculty in dermatology, oncology, and pathology, I was able to master the art of integrating clinical findings, histopathologic features, clinical laboratory data, and molecular characteristics to reach to the diagnosis and most suitable treatment. After my fellowship I was appointed as an attending physician in the cutaneous lymphoma clinic at Tel Aviv Sourasky Medical Center in Israel and provided care for patients with cutaneous lymphomas while continuing to pursue research in the field.
In early 2023 I returned to New York to the cutaneous lymphoma clinic at MSKCC as an associate attending. Other than clinical work and research, I dedicate a large portion of my time and effort to teaching and mentoring students, residents, fellows and visiting physicians. My research projects have been published in the leading dermatology, hematology and oncology journals and I’ve been invited and chosen to present my works in numerous regional, national and international conferences (ASH, USCLC, WCCL, EORTC, SID, AAD, EADV and others). I’m frequently asked to peer-review manuscripts on lymphomas of the skin and I also assist the cutaneous lymphoma foundation (CLF) with the preparation of patients’ education materials and lectures.
Resource links for this episode available at Scholars in Medicine.
Late-breaking abstracts from the AAD Meeting offer a sneak peek into dermatology’s future—and we’ve done the heavy lifting for you. Derms on Drugs uncovers the hottest data that will dominate the top journals and meetings in 2025: the cutting-edge for psoriasis, new Tyk2 inhibitors, new treatment for cutaneous lupus, dupilumab’s possible role in bullous pemphigoid, patient-led patch testing innovations, plus fresh approaches to skin cancer and alopecia areata. Tune in to stay ahead of the curve!
This podcast is brought to you by Scholars in Medicine.
New Articles on causes and treatments for AKs, Melasma, Atopic Derm, Acne, Grover's and Contact Derm. But you can't always believe what you read in a journal, and even when you can it doesn't mean it's going to help your patients. So, sit back, relax and join the Derms on Drugs to separate fact from fiction.
Derms on Drugs is brought to you by Scholars in Medicine.
Resource links for this episode available at Scholars in Medicine.
The Derms on Drugs enlist the Sultan of Scratching, Dan Kaplan from the University of Pittsburgh, to answer the age- old question - should you scratch an itch or not?
Believe it or not, some of the most cutting-edge science on the planet is focusing on this question (you think they'd have better stuff to work on, but who are we to judge). The answer(s) are going to surprise you - turns out scratching does a lot more than just get bugs off our skin (although that part is important too).
Derms on Drugs is brought to you by Scholars in Medicine.
Guest: Daniel H. Kaplan, MD, PhD
Daniel H. Kaplan, MD, PhD is a Professor within the Department of Dermatology and Immunology, University of Pittsburgh. His research is dedicated to understanding the mechanisms that underlie skin immunity and the interplay of different immune cells types that reside in the skin. As a graduate student at Washington University, St Louis he participated in the re-invigoration of the concept of tumor immunosurveillance by observing an increased frequency of skin tumors in immunodeficient mice. During his post-doc at Yale University, he developed a number of mouse lines with a selective deficiency of Langerhans cells (LC) and showed that these cells have the unexpected capacity to suppress tissue immune. As an Assistant and later Associate professor at the University of Minnesota, he found that LC and dermal dendritic cells have unique functions in the development of anti-pathogen responses. In 2015 he moved to the University of Pittsburgh. His laboratory is currently focused on understanding how intracellular communication mechanisms between immune cells and non-hematopoietic cells in the skin with a particular emphasis on sensory afferents modulate cutaneous immunity and skin disease.
Resource links for this episode are available at Scholars in Medicine.
The Captain of Compliance, The Admiral of Adherence... Whatever you want to call him, you're going to love this week's episode as the Derms on Drugs dig deep with Dr. Steve Feldman on how to help our patients actually follow through with our recommendations. Trust us, even if you've heard Dr. Feldman talk about this before, you're still not going to want to miss this.
As part of our dive into the nitty gritty of adherence we'll also talk about:
-The first "Oral Biologic" on the way from Janssen - is this oral peptide that inhibits IL-23 a real game changer?
-How a drug like VTAMA is a game changer for pediatric atopic dermatitis, both because of how well it works and because it's so easy for patients to use
-If Cabtreo, the new triple combo cream for acne, works so fast that it actually helps patients stick with using it
Derms on Drugs is brought to you by Scholars in Medicine.
Guest:
Dr. Steven R. Feldman, MD, PhD is a Professor of Dermatology, Pathology, and Social Sciences & Health Policy at the Wake Forest School of Medicine. His chief clinical interest is psoriasis. Feldman has done groundbreaking research on addiction to tanning beds, patients’ adherence to their medication treatment regimens, and patients’ satisfaction with their medical care. Feldman’s experiences in medicine have led him to try to see how others perceive things, leading to his book Compartments and his recent novella Bent Toward Justice. His research has been published in over 1,000 peer reviewed, Medline-referenced articles. Expertscape.com ranks Feldman among the top experts in the world on psoriasis, acne, dermatology, and treatment adherence. Feldman also serves as the editor of the Journal of Dermatological Treatment and the Journal of Dermatology and Dermatological Surgery and as chief medical editor of The Dermatologist.
Resources:
1. FRONTIER-2: A phase 2b, long-term extension, dose-ranging study of oral JNJ-77242113 for the treatment of moderate-to-severe plaque psoriasis
https://pubmed.ncbi.nlm.nih.gov/39549848/
2. Tapinarof cream 1% once daily: Significant efficacy in the treatment of moderate to severe atopic dermatitis in adults and children down to 2 years of age in the pivotal phase 3 ADORING trials
https://pubmed.ncbi.nlm.nih.gov/38777187/
3. Efficacy and Safety of a Fixed-Dose Clindamycin Phosphate 1.2%, Benzoyl Peroxide 3.1%, and Adapalene 0.15% Gel for Moderate-to-Severe Acne: A Randomized Phase II Study of the First Triple-Combination Drug
https://pubmed.ncbi.nlm.nih.gov/34674160/
4. An exploratory study of adherence to topical benzoyl peroxide in patients with acne vulgaris
https://pubmed.ncbi.nlm.nih.gov/19389536/
5. Effects of ruxolitinib cream on pruritus and quality of life in atopic dermatitis: Results from a phase 2, randomized, dose-ranging, vehicle- and active-controlled study
https://pubmed.ncbi.nlm.nih.gov/32057960/
6. Long-term adherence to topical psoriasis treatment can be abysmal: a 1-year randomized intervention study using objective electronic adherence monitoring
https://pubmed.ncbi.nlm.nih.gov/27664969/
